IPO registrations (S-1, F-1) · Registrants
Aditxt, Inc.
- SEC CIK
- 1726711 · filings on EDGAR ↗
- Former names
- ADiTx Therapeutics, Inc. (2020–2021); Aditx Therapeutics, Inc. (2020–2021)
- Registration
- Form S-1, first filed 2020-01-15, last 2025-06-20; 9 initial registrations, 16 amendments
- Outcome
- Final prospectus filed 2020-07-01; declared effective 2020-06-29; withdrawal requested 2023-09-22
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 737 N. FIFTH STREET, SUITE 200, Richmond, VA 23219
- EIN
- 82-3204328
- Ticker
- ADTX
- EDGAR entity type
- operating
- Insiders and CEO pay
- Aditxt, Inc. on the corporate pages
On this site
- Business registration: Aditxt, Inc. Fuzzy (name and state)
- Form D issuer: Aditxt, Inc. EXACT (CIK (EXACT))
- Lobbying client: ADITXT INC. Fuzzy (name and state)
- SEC filer: Aditx Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-01-15 | S-1 | S-1 (registration) | ADiTx Therapeutics, Inc. | 0001213900-20-001135 ↗ |
| 2020-02-07 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-002914 ↗ |
| 2020-02-19 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-004282 ↗ |
| 2020-04-28 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-010308 ↗ |
| 2020-05-14 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-012077 ↗ |
| 2020-05-29 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-013734 ↗ |
| 2020-06-17 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015193 ↗ |
| 2020-06-24 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015613 ↗ |
| 2020-06-25 | S-1/A | S-1/A (amendment) | ADiTx Therapeutics, Inc. | 0001213900-20-015750 ↗ |
| 2020-06-29 | EFFECT | EFFECT (declared effective) | ADiTx Therapeutics, Inc. | 9999999995-20-001668 ↗ |
| 2020-07-01 | 424B4 | 424B4 (final prospectus) | ADiTx Therapeutics, Inc. | 0001213900-20-016472 ↗ |
| 2020-08-28 | S-1 | S-1 (registration) | ADiTx Therapeutics, Inc. | 0001213900-20-024322 ↗ |
| 2020-09-01 | EFFECT | EFFECT (declared effective) | ADiTx Therapeutics, Inc. | 9999999995-20-002338 ↗ |
| 2020-09-02 | S-1MEF | S-1MEF (added securities) | ADiTx Therapeutics, Inc. | 0001213900-20-024908 ↗ |
| 2020-09-03 | 424B4 | 424B4 (final prospectus) | ADiTx Therapeutics, Inc. | 0001213900-20-025234 ↗ |
| 2021-02-04 | S-1 | S-1 (registration) | Aditx Therapeutics, Inc. | 0001213900-21-006626 ↗ |
| 2021-02-10 | EFFECT | EFFECT (declared effective) | Aditx Therapeutics, Inc. | 9999999995-21-000565 ↗ |
| 2021-07-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-21-002744 ↗ |
| 2022-07-18 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-22-039769 ↗ |
| 2022-09-15 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056026 ↗ |
| 2022-09-15 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056228 ↗ |
| 2022-09-16 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-22-056371 ↗ |
| 2022-09-16 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-22-002729 ↗ |
| 2022-09-20 | 424B4 | 424B4 (final prospectus) | Aditxt, Inc. | 0001213900-22-057179 ↗ |
| 2023-06-29 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-052531 ↗ |
| 2023-09-15 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-077044 ↗ |
| 2023-09-21 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-23-002719 ↗ |
| 2023-09-22 | RW | RW (withdrawal request) | Aditxt, Inc. | 0001213900-23-078579 ↗ |
| 2023-11-07 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-23-084402 ↗ |
| 2023-11-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-23-003339 ↗ |
| 2024-01-18 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-24-004519 ↗ |
| 2024-01-26 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-007068 ↗ |
| 2024-02-14 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-013683 ↗ |
| 2024-05-14 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-042539 ↗ |
| 2024-06-05 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-050059 ↗ |
| 2024-06-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-001830 ↗ |
| 2024-08-06 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-002435 ↗ |
| 2024-09-11 | S-1/A | S-1/A (amendment) | Aditxt, Inc. | 0001213900-24-077771 ↗ |
| 2024-09-13 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-24-002845 ↗ |
| 2025-06-20 | S-1 | S-1 (registration) | Aditxt, Inc. | 0001213900-25-056288 ↗ |
| 2025-06-30 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-25-002100 ↗ |
| 2026-04-21 | EFFECT | EFFECT (declared effective) | Aditxt, Inc. | 9999999995-26-001275 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Albanna Amro A. | Director,Officer; Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 8 | 2020–2023 | |
| ANTHONY LAURA E | Director | 4 | 2020–2021 | ||
| Brady Brian Michael | Director | 6 | 2020–2025 | ||
| Pankovcin Corinne | Officer | CCO; CHIEF FINANCIAL OFFICER; Chief M&A Officer | 7 | 2020–2025 | |
| Shabahang Shahrokh | Director,Officer; Officer | Chief Innovation Officer; CHIEF INNOVATION OFFICER | 8 | 2020–2023 | |
| Kiaie Namvar | Director | 5 | 2020–2021 | ||
| Albanna Rowena | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 8 | 2020–2023 | |
| McLeod Rosland Fisher | Director | 1 | 2020 | ||
| Runge Jeffrey W. | Director | 7 | 2020–2023 | ||
| Farley Thomas J | Officer | Chief Financial Officer; PRINCIPAL ACCOUNTING OFFICER | 4 | 2021–2023 | |
| Chung Lauren | Director | 2 | 2021 | ||
| Shatzkes Matthew | Officer | Chief Legal Officer and GC | 1 | 2022 | |
| BNP PARIBAS SECURITIES CORP | Other; TenPercentOwner | 2 | 2023 | ||
| Nelson Charles Athle | Director | 2 | 2023 | ||
| HRT FINANCIAL LP | TenPercentOwner | 15 | 2024–2026 | ||
| PELLETIER SAUNDRA L | Director | 1 | 2025 | ||
| Hermina Sylvia | Director | 1 | 2025 | ||
| Porcelli Christopher Jon | Officer | General Counsel, CPO & CS | 1 | 2025 | |
| Gong Sandie | TenPercentOwner | 2 | 2026 | ||
| Xu Devon Xin | TenPercentOwner | 2 | 2026 | ||
| BANK OF AMERICA CORP /DE/ | TenPercentOwner | 2 | 2026 | ||
| BANK OF AMERICA NA | TenPercentOwner | 2 | 2026 | ||
| BOFA SECURITIES, INC. | TenPercentOwner | 2 | 2026 | ||
| DRW Securities, LLC | TenPercentOwner | 2 | 2026 | ||
| Takeover Time 2026 LLC | TenPercentOwner | 2 | 2026 | ||
| Tai Wey Ann | TenPercentOwner | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-01-23 | Aditxt, Inc. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2023-09-20 | Aditxt, Inc. | Biotechnology | $10,000,000 | $10,000,000 | 1 | 1 |
| 2022-08-17 | Aditxt, Inc. | Biotechnology | $2,200,000 | $2,033,333 | 6 | 1 |
| 2021-01-26 | Aditx Therapeutics, Inc. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2018-12-26 | ADiTx Therapeutics, Inc. | Biotechnology | $2,000,000 | $109,800 | 4 | 1 |
| 2018-03-29 | ADiTx Therapeutics, Inc. | Biotechnology | $2,000,000 | $262,500 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.